Advertisement

Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody

Published:April 02, 2009DOI:https://doi.org/10.1016/j.jaci.2009.01.069
      The criteria for the diagnosis of hypereosinophilic syndrome (HES) are blood eosinophilia equal to or exceeding 1.5 × 109/L, usually for a period of greater than 6 consecutive months; no underlying cause of eosinophilia, such as parasitic infection; and evidence of eosinophil-mediated organ damage.
      • Klion A.D.
      • Bochner B.S.
      • Gleich G.J.
      Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.
      The principal target organs are the heart, skin, and nervous system. Intracavitary thrombi might develop on damaged endocardium and disseminate throughout the circulatory system. Prognosis in HES is variable; it can be asymptomatic or progress rapidly to heart failure or acute leukemia.
      • Roufosse F.
      • Cogan E.
      • Goldman M.
      The hypereosinophilic syndrome revisited.
      To read this article in full you will need to make a payment

      References

        • Klion A.D.
        • Bochner B.S.
        • Gleich G.J.
        Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.
        J Allergy Clin Immunol. 2006; 117: 1292-1302
        • Roufosse F.
        • Cogan E.
        • Goldman M.
        The hypereosinophilic syndrome revisited.
        Annu Rev Med. 2003; 54: 169-184
        • Gleich G.J.
        • Leiferman K.M.
        • Pardanani A.
        • Tefferi A.
        • Butterfield J.H.
        Treatment of hypereosinophilic syndrome with imatinib mesilate.
        Lancet. 2002; 359: 1577-1578
        • Cools J.
        • DeAngelo D.J.
        • Gotlib J.
        • Stover E.H.
        • Legare R.D.
        • Cortes J.
        • et al.
        A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
        N Engl J Med. 2003; 348: 1201-1214
        • Rothenberg M.E.
        • Klion A.D.
        • Roufosse F.E.
        • Kahn J.E.
        • Weller P.F.
        • Su H.
        • et al.
        Treatment of patients with hypereosinophilic syndrome with mepolizumab.
        N Engl J Med. 2008; 358: 1215-1228
        • Dumont F.J.
        Alemtuzumab (Millennium/Ilex).
        Curr Opin Investig Drugs. 2001; 2: 139-160
        • Elsner J.
        • Hochstetter R.
        • Spiekermann K.
        • Kapp A.
        Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils.
        Blood. 1996; 88: 4684-4693
        • Pitini V.
        • Teti D.
        • Arrigo C.
        • Righi M.
        Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.
        Br J Haematol. 2004; 127: 477
        • Sefcick A.
        • Sowter D.
        • Dasgupta E.
        • Russell N.H.
        • Byrne J.L.
        Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.
        Br J Haematol. 2004; 124: 558-559